TREX1 and prostate neoplasm: Notably, our analysis identified TREX1 as a critical determinant of poor clinical outcome; TREX1 is significantly overexpressed in prostate tumor tissues, and its knockdown markedly inhibits prostate cancer cell proliferation, migration, and invasion in vitro.